Valion Bio advances oral mucosal Entolimod formulation program for acute radiation syndrome
VBIO•Valion Bio completed formulation work on an oral mucosal version of investigational Entolimod using SKL’s BioViscid platform. No clinical trial launch or human study results were disclosed.
1. Formulation work completed
Valion Bio said it completed formulation work for an oral mucosal version of investigational radiation drug Entolimod using SKL’s BioViscid platform. The needle-free approach is intended to support rapid, large-scale deployment for acute radiation syndrome preparedness; no clinical trial launch or human study readout was disclosed.
2. Parallel development paths
The company cited prior animal research on injected Entolimod suggesting protective effects when given before exposure and improved survival when administered afterward. Injectable development will continue in parallel with the oral mucosal program, with no timeline for future development provided.
